The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | The integration of novel agents and allogeneic transplant in myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, Spain, discusses the integration of novel agents and allogeneic transplant in myelofibrosis (MF), highlighting that, unlike in other hematological malignancies, novel agents have not reduced the need for transplantation in this disease. Dr Hernández-Boluda notes that the introduction of novel agents provides more opportunities to improve patient condition prior to transplant, but may also pose the risk of delaying this curative treatment option. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Tomorrow we have a very interesting talk on the interaction between the new novel therapies and the allotransplant indication in chronic malignancies. My talk is going to deal with myelofibrosis. And what I think, while in other diseases like CML, CLL, novel drugs have completely changed the indication of transplant, have reduced the numbers, in myelofibrosis, they have not...
Tomorrow we have a very interesting talk on the interaction between the new novel therapies and the allotransplant indication in chronic malignancies. My talk is going to deal with myelofibrosis. And what I think, while in other diseases like CML, CLL, novel drugs have completely changed the indication of transplant, have reduced the numbers, in myelofibrosis, they have not. Actually, the indication of transplant in this disease is increasing over time. So I think the advantage of new drugs is that you have more options to improve the general condition of the patient or control the disease manifestation, the spleen size, and so on, as a preparation for transplant. And the risk of the novel therapies, so far, the ones that we have, is that you may possibly delay the transplant and lose the window of having this curative therapy for our patients. So this is the type of aspects that I am going to be dealing with tomorrow.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
